Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAZOLAMIDE vs DICHLORPHENAMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reversible inhibition of carbonic anhydrase, primarily in the proximal renal tubule, reducing hydrogen ion secretion and increasing bicarbonate, sodium, potassium, and water excretion. Also reduces aqueous humor formation via ocular carbonic anhydrase inhibition.
Dichlorphenamide is a carbonic anhydrase inhibitor. It inhibits the enzyme carbonic anhydrase in the proximal renal tubule, reducing reabsorption of bicarbonate, leading to metabolic acidosis, and decreasing intraocular pressure by reducing aqueous humor formation.
Edema due to congestive heart failure (adjunctive therapy),Drug-induced edema,Centrencephalic epilepsies (petit mal, unlocalized seizures),Chronic simple (open-angle) glaucoma,Secondary glaucoma,Preoperative lowering of intraocular pressure in acute angle-closure glaucoma,Altitude sickness (prevention and treatment),Off-label: Idiopathic intracranial hypertension, metabolic alkalosis, sleep apnea, bipolar disorder, cystinuria, hypokalemic periodic paralysis
Treatment of increased intraocular pressure in chronic open-angle glaucoma,Secondary glaucoma,Preoperatively in acute angle-closure glaucoma,Off-label: Treatment of familial periodic paralysis,Off-label: Management of altitude sickness
250-500 mg orally twice daily or 250 mg intravenously twice daily; for edema, 250-375 mg orally once daily; for altitude sickness, 250 mg orally every 8-12 hours.
25-50 mg orally twice daily.
Terminal half-life approximately 10–15 hours; prolonged in renal impairment (up to 30+ hours).
Terminal elimination half-life of 2-4 hours; increased in renal impairment, up to 12-24 hours in severe insufficiency.
Primarily excreted unchanged in urine (70-100%). Minor metabolism via hydrolysis of acetyl group (possibly by plasma esterases) to acetazolamide, and glucuronide conjugation.
Dichlorphenamide is not extensively metabolized; it is excreted unchanged in urine.
Renal: ~90% unchanged drug via tubular secretion and glomerular filtration; minor biliary/fecal (<2%).
Primarily renal via tubular secretion; 50-70% excreted unchanged in urine; minor biliary/fecal elimination (<20%).
~70–90% bound primarily to carbonic anhydrase in erythrocytes and plasma proteins (albumin).
90-95% bound to plasma proteins, primarily albumin.
0.2–0.3 L/kg; concentrates in tissues with high carbonic anhydrase content (RBCs, kidneys, eyes).
0.2-0.3 L/kg; low Vd indicates limited extravascular distribution, consistent with high protein binding.
Oral: ~100% (well absorbed); IV: 100%.
Oral: approximately 80-100% (well absorbed); bioavailability not defined for parenteral routes as not typically given.
Cr Cl 10-50 m L/min: administer every 12 hours; Cr Cl <10 m L/min: avoid use (ineffective).
Cr Cl <50 m L/min: not recommended; Cr Cl 50-80 m L/min: 25 mg once daily; Cr Cl >80 m L/min: no adjustment.
Child-Pugh class A: no adjustment; Child-Pugh class B-C: caution, reduce dose by 50% and monitor for encephalopathy.
Child-Pugh A: no adjustment; Child-Pugh B: 25 mg once daily; Child-Pugh C: avoid use.
Children: 5-10 mg/kg/dose orally or IV every 8-12 hours; maximum 500 mg/dose.
Not established; safety and efficacy not determined in children.
Initiate at lowest effective dose (250 mg daily) due to increased risk of electrolyte disturbances and renal impairment.
Start at 25 mg once daily; monitor renal function and electrolytes.
WARNING: Metabolically induced acidosis. Use with caution in patients with hepatic cirrhosis to avoid precipitation of hepatic encephalopathy. Not recommended for long-term use in patients with chronic noncongestive angle-closure glaucoma due to risk of increased intraocular pressure with lens displacement.
None.
Sulfonamide hypersensitivity reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) - discontinue at first sign of rash,Metabolic acidosis - monitor electrolytes, use with caution in patients with respiratory acidosis or those at risk,Hepatic impairment - contraindicated in cirrhosis; may precipitate hepatic encephalopathy,Renal impairment (Cr Cl <10 m L/min) - ineffective and may cause metabolic acidosis,Hematologic reactions (agranulocytosis, aplastic anemia) - monitor CBC,Hypercalciuria and renal stone formation - ensure adequate hydration,Drowsiness, confusion, fatigue - impaired ability to drive/operate machinery,Use in pregnancy - potential risk; cross-sensitivity with sulfonamides
Metabolic acidosis: Can occur, especially in patients with renal impairment or electrolyte disturbances.,Hypokalemia: Risk may increase due to bicarbonate loss and metabolic acidosis.,Sulfonamide allergy: Cross-sensitivity possible; caution in patients with history of sulfonamide hypersensitivity.,Renal impairment: Use with caution; may accumulate and worsen acidosis.,Hepatic impairment: Caution due to risk of hepatic encephalopathy.,Drug interactions: May increase effects of other carbonic anhydrase inhibitors, furosemide, and decrease effects of lithium.,Pregnancy: Weigh risks vs benefits; not recommended.,Lactation: Excreted in milk; avoid breastfeeding.
Hypersensitivity to acetazolamide or any sulfonamide derivative,Severe hepatic cirrhosis or hepatic impairment,Severe renal impairment (Cr Cl <10 m L/min) or anuria,Hyponatremia or hypokalemia,Adrenocortical insufficiency (Addison's disease),Long-term use in chronic noncongestive angle-closure glaucoma,Metabolic acidosis
Hypersensitivity to dichlorphenamide or other sulfonamides,Severe renal impairment (e.g., anuria, severe nephropathy),Severe hepatic disease,Hepatic encephalopathy,Hypokalemia (uncorrected),Metabolic acidosis (uncorrected),Adrenal insufficiency,Hyperchloremic acidosis,Pregnancy (relative contraindication),Lactation (relative contraindication)
Avoid high doses of vitamin C or cranberry juice as they may acidify urine and decrease drug effectiveness. Maintain adequate hydration; no specific food restrictions.
Avoid high-dose aspirin or salicylates; may increase toxicity. Limit alcohol intake to reduce risk of metabolic acidosis. No specific food restrictions but maintain adequate hydration to prevent renal calculi. Avoid cranberry juice if prone to kidney stones.
First trimester: Avoid; associated with increased risk of congenital malformations (limb defects, hypospadias). Second and third trimesters: Use only if clearly needed; may cause fetal metabolic acidosis, electrolyte disturbances, and growth retardation.
Dichlorphenamide is a carbonic anhydrase inhibitor. Data in pregnant women are insufficient. In animal studies, it has been associated with fetal skeletal abnormalities and reduced fetal weight at doses similar to human therapeutic doses. First trimester exposure may carry a risk of teratogenicity; second and third trimester risks include possible metabolic acidosis and electrolyte disturbances in the fetus.
Excreted into breast milk (M/P ratio approximately 0.25). Not recommended due to risk of sulfonamide-related adverse effects (e.g., kernicterus in jaundiced infants, hemolytic anemia in G6PD deficiency).
It is not known whether dichlorphenamide is excreted in human breast milk. The M/P ratio is unknown. Due to the potential for serious adverse effects in nursing infants, a decision should be made whether to discontinue breastfeeding or discontinue the drug.
No standard dose adjustment recommended; pharmacokinetics altered (increased Vd, decreased Cmax) but clinical significance uncertain. Monitor for metabolic acidosis and adjust if necessary.
No specific dose adjustments for pregnancy are established. However, due to pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced renal clearance), careful monitoring of drug effect and tolerability is recommended. Dose may need individualized titration.
Acetazolamide is a carbonic anhydrase inhibitor used for glaucoma, altitude sickness, and as a diuretic. Monitor serum electrolytes (especially potassium and bicarbonate) due to metabolic acidosis risk. Avoid in severe hepatic or renal impairment. Can cause paresthesias, especially in hands and feet. Use with caution in patients with sulfonamide allergy as cross-reactivity is possible but rare.
Dichlorphenamide is a carbonic anhydrase inhibitor used for primary open-angle glaucoma and familial periodic paralysis. Monitor serum potassium and perform baseline/periodic blood counts due to risk of hypokalemia and bone marrow suppression. Contraindicated in hepatic cirrhosis due to risk of hepatic encephalopathy. Can cause metabolic acidosis; use cautiously in patients with respiratory acidosis or COPD. Dose adjustment required in renal impairment. May increase urate levels; avoid in gout unless urate-lowering therapy is used.
Take exactly as prescribed; do not stop suddenly.,May cause tingling or numbness in fingers, toes, or mouth; this is usually temporary.,Drink plenty of fluids unless otherwise directed; avoid excessive alcohol.,Report unusual fatigue, muscle cramps, or rapid breathing to your doctor.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,If used for altitude sickness, start 1-2 days before ascent and continue during climb.
Take exactly as prescribed; do not skip doses to prevent glaucoma progression.,Report any signs of bleeding, bruising, fever, or sore throat immediately.,May cause drowsiness; avoid driving or operating heavy machinery until effects known.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol and aspirin-containing products to reduce risk of metabolic acidosis.,Drink plenty of fluids to prevent kidney stones; maintain adequate hydration.,Notify doctor if you have liver disease, kidney stones, or breathing problems.,This may increase blood sugar; monitor if diabetic.,Taste disturbances or altered sense of taste may occur and are usually reversible.
"Bosutinib, a potent CYP3A4 inhibitor, can significantly increase the serum concentration of acetazolamide, a carbonic anhydrase inhibitor, by reducing its hepatic metabolism. This elevation may potentiate acetazolamide's adverse effects, including metabolic acidosis, electrolyte imbalances (e.g., hypokalemia), and paresthesias, especially in patients with renal impairment. Clinicians should monitor for signs of acetazolamide toxicity when coadministered with bosutinib."
"Acetazolamide, a carbonic anhydrase inhibitor, can cause metabolic acidosis and decrease renal tubular secretion of metformin, potentially increasing metformin plasma concentrations. This combination may elevate the risk of lactic acidosis, a rare but serious adverse effect of metformin. Additionally, acetazolamide-induced hypokalemia can exacerbate metformin-associated hyperlactatemia."
"Acetazolamide, a carbonic anhydrase inhibitor, increases urinary pH and promotes bicarbonate excretion, leading to metabolic alkalosis. This systemic alkalinization enhances renal tubular reabsorption of lithium, paradoxically decreasing lithium clearance and increasing serum lithium concentrations. Clinically, this can precipitate lithium toxicity, manifesting as nausea, tremor, ataxia, or confusion, particularly in patients on stable lithium regimens."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAZOLAMIDE vs DICHLORPHENAMIDE, answered by our medical review team.
ACETAZOLAMIDE is a Carbonic Anhydrase Inhibitor that works by Reversible inhibition of carbonic anhydrase, primarily in the proximal renal tubule, reducing hydrogen ion secretion and increasing bicarbonate, sodium, potassium, and water excretion. Also reduces aqueous humor formation via ocular carbonic anhydrase inhibition.. DICHLORPHENAMIDE is a Carbonic Anhydrase Inhibitor that works by Dichlorphenamide is a carbonic anhydrase inhibitor. It inhibits the enzyme carbonic anhydrase in the proximal renal tubule, reducing reabsorption of bicarbonate, leading to metabolic acidosis, and decreasing intraocular pressure by reducing aqueous humor formation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAZOLAMIDE and DICHLORPHENAMIDE depend on the specific clinical indication. These are both Carbonic Anhydrase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAZOLAMIDE is: 250-500 mg orally twice daily or 250 mg intravenously twice daily; for edema, 250-375 mg orally once daily; for altitude sickness, 250 mg orally every 8-12 hours.. The standard adult dose of DICHLORPHENAMIDE is: 25-50 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAZOLAMIDE and DICHLORPHENAMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAZOLAMIDE is classified as Category C. First trimester: Avoid; associated with increased risk of congenital malformations (limb defects, hypospadias). Second and third trimesters: Use only if clearly needed; may cause f. DICHLORPHENAMIDE is classified as Category C. Dichlorphenamide is a carbonic anhydrase inhibitor. Data in pregnant women are insufficient. In animal studies, it has been associated with fetal skeletal abnormalities and reduced. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.